Dogwood Therapeutics, INC Form 4 insider transactions

Director Richard Alan Burch acquired stock options in Virios Therapeutics, Inc. on February 26, 2024.

Director Abel De La Rosa acquired stock options in Virios Therapeutics, Inc. on February 26, 2024.

Angela Walsh, SVP of Finance at Virios Therapeutics, acquired stock options exercisable for 63,618 shares of common stock on February 26, 2024.

Ralph Grosswald, SVP of Operations at Virios Therapeutics, reports the acquisition of stock options.

Roger Michael Gendreau, Chief Medical Officer of Virios Therapeutics, Inc., was granted stock options to purchase 88,085 shares of common stock on February 26, 2024.

Gregory Scott Duncan, CEO of Virios Therapeutics, acquired 138,835 stock options on February 26, 2024, as reported in a Form 4 filing with the SEC.